Evogene Ltd. (EVGN) Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Sector: Agricultural Chemicals
Industry: Biotechnology
Evogene Ltd. NASDAQ:EVGN Healthcare · Biotechnology
Mkt Cap $6.14M
EV -
SI 0.5%
Net Cash/Sh -
AH After hours +8.76%$0.3699 Prev close $0.3917 -13.17%Close $0.3401 +8.76%Now $0.3699 VOL 254K $ Vol $92K RVOL 0.47x
Mkt Cap $6.14M
EV -
VOL 254K sh
$ Vol $92K
RVOL 0.47×
SI 0.5%
Net Cash/Sh -
Press Release
AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
Evogene's subsidiary AgPlenus reported progress in two fungicide discovery programs targeting novel modes of action against Septoria tritici blotch, a major wheat disease. Active molecules generated by its ChemPass AI for Ag platform showed fungicidal activity including against resistant Septoria strains, reduced disease by 75% in plant tissue assays, and were independently corroborated by an external research organization.
• 11h ago AI analysis › Press Release
Evogene Schedules Third Quarter 2026 Financial Results Release
Evogene will release its third quarter 2026 financial results on Thursday, November 19, 2026. Management will host a Zoom conference call the same day at 9:00 AM Eastern Time to discuss the results; advance registration is required and a replay will be posted on the company website.
• 12d ago AI analysis › Press Release
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Evogene named acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program, aiming at a potential first-in-class small molecule for steroid-refractory patients. In several months the company generated novel, patentable small-molecule candidates with nanomolar potency, using its ChemPass AI platform to screen a virtual space of more than 110 billion molecules, with input from aGVHD experts at Dana-Farber and University Medical Center Freiburg.
• 20d ago AI analysis › Press Release
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
Evogene announced it will attend BIO-Europe in Cologne, Germany (November 9-11, 2026) and present a scientific poster at Drug Discovery Chemistry Europe in Barcelona, Spain (November 10-12, 2026). At BIO-Europe, Chief Development Officer Dr. Gabi Tarcic will hold one-on-one meetings with potential partners on AI-driven small-molecule collaboration opportunities. In Barcelona, the company will showcase its ChemPass AI platform spanning virtual screening, QSAR-driven hit-to-lead, and generative de novo design.
• 22d ago AI analysis › Press Release
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
Evogene will participate in an AI Drug Discovery Roadshow across the U.S. East Coast, November 2-5, 2026, organized by the Israel Export Institute and TradeIL. CEO Ofer Haviv will present the company's ChemPass AI generative platform and hold meetings with investors, pharmaceutical companies, and potential strategic partners.
• 28d ago AI analysis › Press Release
Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors
Evogene entered a cooperation agreement with the Pure Capital Group resolving all disputes, including claims over the September 4 AGM voting results and a threatened Section 328 special tender offer under Israeli law. The board will be reconstituted at seven directors: four Pure Capital nominees replacing Dr. Yael Margolin, Mr. Yoshinori Oikawa, Mr.
• 1mo ago AI analysis › Press Release
Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance
Nasdaq granted Evogene an additional 180-day period, until March 29, 2027, to regain compliance with the $1.00 minimum bid price rule after its shares traded below $1.00. Compliance requires a closing bid of at least $1.00 for ten consecutive business days; failure to cure by the deadline would trigger delisting notification.
• 1mo ago AI analysis › Press Release
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
Evogene urged shareholders to vote for its board nominees at the September 4 Annual Meeting, opposing dissident shareholders L.I.A. Pure Capital and Invest-Pro who seek a complete board replacement. The company defended its 18-month transformation, citing a drastic reduction in annual cash burn to $8.5–$9.5 million from $20.5 million and a headcount reduction from 117 to 38 employees. Management highlighted six new drug-development agreements and the monetization of subsidiary Lavie Bio for $15.25 million as evidence of commercial progress and effective capital allocation.
• 2mo ago AI analysis › Press Release
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
Institutional Shareholder Services (ISS) and Glass Lewis have recommended that Evogene shareholders vote 'FOR' the company's director nominees at the upcoming Annual General Meeting, backing the incumbent board against a dissident slate. The proxy advisors criticized the dissident campaign led by L.I.A. Pure Capital and Invest-Pro, stating it failed to present a compelling case for change and highlighted the relevant experience of the management's nominees.
• 2mo ago AI analysis › Press Release ● Major
Evogene Reports Second Quarter and First Half 2026 Financial Results
Evogene reduced its second-quarter net loss to $1.8 million from $4.7 million a year ago, driven by a strategic transformation that cut the workforce from 117 to 38 employees and lowered annual cash burn guidance to $8.5–$9.5 million. The company raised $11.1 million since 2025 and holds $9.3 million in cash, while expanding its ChemPass AI platform to 110 billion molecules and securing six active drug collaborations.
• 2mo ago AI analysis › Press Release
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Evogene announced that Chairman Nir Nimrodi will join the upcoming quarterly results conference call on August 18 to specifically address the situation involving dissident shareholders. Mr. Nimrodi intends to discuss the company's perspective on these developments and the potential implications of the dissidents' attempted actions for Evogene and its shareholders.
• 3mo ago AI analysis › Press Release
Evogene Schedules Second Quarter 2026 Financial Results Release
Evogene Ltd. announced that it will release its financial results for the second quarter of 2026 on Tuesday, August 18, 2026. Management is scheduled to host a conference call later that day at 9:00 AM Eastern Time to discuss the quarterly performance.
• 3mo ago AI analysis › Press Release
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Evogene partnered with ELEO Inc. to discover and develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The collaboration combines Evogene's ChemPass AI platform with ELEO's biological expertise to address a market projected to grow from $4.4 billion in 2025 to more than $23 billion by 2035.
• 3mo ago AI analysis › Press Release
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
AgPlenus, a subsidiary of Evogene Ltd. (EVGN), launched the Antifungal Potency Predictor (APP), a machine learning model designed to forecast the efficacy of fungicides from their chemical structure. The APP model integrates with Evogene's ChemPass AI for Ag™ platform to prioritize high-probability candidates prior to synthesis, aiming to lower R&D costs and accelerate the discovery of novel modes of action.
• 4mo ago AI analysis › Press Release
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Evogene partnered with Tel Aviv University's Blavatnik Center for Drug Discovery to launch a joint initiative aimed at accelerating AI-driven small-molecule drug discovery. The collaboration combines Evogene's ChemPass AI computational engine with BCDD's experimental infrastructure to support academic entrepreneurs in translating novel disease targets into viable drug candidates.
• 4mo ago AI analysis › Press Release
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
Evogene announced a major milestone in its collaboration with Google Cloud, successfully integrating agentic computational systems into its ChemPass AI™ platform. The enhanced engine, powered by Google's Gemini models, enables earlier definition of biological and clinical success criteria, aiming to accelerate discovery timelines and improve scalability.
• 4mo ago AI analysis › Press Release
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene will present its pharma division achievements at the BIO International Convention in San Diego on June 23, 2026. Dr. Gabi Tarcic will deliver an oral presentation on AI-driven small-molecule discovery and the capabilities of ChemPass AI™.
• 5mo ago AI analysis › Press Release
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab for advanced solid tumors. The open-label study enrolled 11 patients who had progressed on prior anti-PD-1 therapy. The trial met its primary endpoint of favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary efficacy signals included one partial response and five patients achieving stable disease beyond the 16-week combination period.
• 5mo ago AI analysis › Press Release
Evogene Reports First Quarter 2026 Financial Results
Evogene reported Q1 2026 revenue of $0.3 million, a significant decline from $2.3 million in the prior year, driven by the wind-down of non-core subsidiaries like Casterra. The company posted a net loss of $5.9 million, widening from $3.0 million year-over-year, largely due to decreased revenues and increased financing expenses related to warrant revaluations.
• 5mo ago AI analysis › Press Release
Evogene to Present at the 24th Schrödinger European User Group Meeting
prnewswire.com • 6mo ago Press Release
Evogene Schedules First Quarter 2026 Financial Results Release
Evogene announced it will release its first quarter 2026 financial results on Wednesday, May 20, 2026. Management will host a conference call later that day at 9:00 AM ET to discuss the results.
• 6mo ago AI analysis ›